ENTRESTO SPRINKLE

Growth

sacubitril and valsartan

Novartis
NDAORALCAPSULE, PELLETS
Approved
Apr 2024
Lifecycle
Growth
Competitive Pressure
0/100

Mechanism of Action

Angiotensin 2 Receptor Antagonists

Pharmacologic Class:

Angiotensin 2 Receptor Blocker

Indications (6)

symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one yearoldercardiovascular deathhospitalization for heart failure in adult patients with chronic heart failureheart failureto reduce the risk of cardiovascular death and hospitalization

Loss of Exclusivity

LOE Date
Feb 2, 2037
132 months away
Patent Expiry
Feb 2, 2037

Patent Records (3)

Patent #ExpiryTypeUse Code
9388134
Nov 8, 2026
U-1723
8877938
May 27, 2027
SubstanceProduct
—
10722471
Feb 2, 2037
Product
U-3896
Company
Novartis
Novartis
BASEL, Switzerland
646 open jobs
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers